Clinical trials: CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (PIDC) is an acquired dysimmune polyneuropathy whose prevalence is estimated to be between 1 to 4 per 100,000 depending on the study, with an incidence of less than 1 per…
- Trial name
- PRONELEC PIDC (NCT03967899)
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A
- Trial name
- NCT02967679
- Testing
- MD1003
- Where
- France
- Volunteers
- 15 people
- Sponsor
- MedDay Pharmaceuticals SA
Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder
Biomarkers in Autoimmune Disease of Nervous System
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves.
- Conditions
- Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis, Guillain-Barre Syndrome
- Trial name
- NCT06502015
- Testing
- biomaker levels
- Where
- China
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
This clinical trial aims to evaluate the safety and efficacy of obinutuzumab β in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The key research objectives are as follows:1.
- Trial name
- NCT07696377
- Testing
- Obinutuzumab β
- Volunteers
- 24 people
- Sponsor
- Zhongming Qiu
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Trial name
- ADHERE (NCT04281472)
- Testing
- efgartigimod PH20 SC in stage B
- Where
- 216 sites in United States, Austria and 23 more
- Volunteers
- 322 people
- Sponsor
- argenx
Charcot-Marie-Tooth, CMT1A
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals…
- Conditions
- Charcot-Marie-Tooth, CMT1A, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyneuropathy Associated With Anti-MAG Antibodies (Anti-MAG Polyneuropathy)
- Trial name
- CMT-NFS (NCT07461896)
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Multiple Sclerosis, NMO Spectrum Disorder
Tongji NADs Cohort
Neurological Autoimmune Diseases (NADs) are disorders caused by abnormal immune system attacks on neural tissues, affecting multiple systems including the central nervous system, peripheral nervous system, and neuromuscular…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- NCT07333196
- Testing
- No active interventions
- Where
- China
- Volunteers
- 1,550 people
- Sponsor
- Tongji Hospital
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of Telitacicept in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- NCT07597733
- Testing
- Conventional Therapy, Telitacicept
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sichuan Academy of Medical Sciences
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Autoimmune Diseases
Transcriptome Analysis of the Peripheral Blood in CIDP
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP.
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Autoimmune Diseases, Clarkson Syndrome, Muscular Autoimmune Disorders
- Trial name
- PHARMACOPID (NCT02404298)
- Testing
- IVIg
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06485232
- Testing
- Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xuanwu Hospital, Beijing
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.
- Trial name
- PRISM (NCT02293460)
- Testing
- I10E
- Where
- 33 sites in France, Italy and 4 more
- Volunteers
- 44 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG)
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
This single-arm, open-label investigator-initiated trial (IIT) evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05 in patients with autoimmune neurological diseases, including Multiple…
- Conditions
- Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Encephalitis (AE)
- Trial name
- NCT07337785
- Testing
- CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Randomized double-blind controlled study of rituximab versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) on chronic treatment with immunoglobulins.
- Trial name
- CIDPRIT (NCT06325943)
- Testing
- Rituximab
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- Istituto Clinico Humanitas
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
The use of neuroimaging in the evaluation of neuromuscular pathologies is a promising and rapidly expandinf field. Among the different imaging techniques employed, nerve ultrasound is of particular interest given it's non…
- Trial name
- NCT04978623
- Testing
- high frequency ultrasound
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy
This prospective, longitudinal study aims to evaluate the usefulness of high-resolution whole-body motion data captured by wearable sensors to assess functional status and longitudinal changes in CIDP (chronic inflammatory…
- Trial name
- MOVE CIDP (NCT07882797)
- Testing
- Xsens motion suit
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people…
- Trial name
- XPERT (NCT07540221)
- Testing
- Gamunex-C, Xembify
- Where
- 15 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Neurological Autoimmune Diseases
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases.
- Trial name
- NCT04687332
- Testing
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- University Medical Center Mainz
Chronic Inflammatory Demyelinating Polyneuropathy
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199).
- Trial name
- NCT07188844
- Testing
- Batoclimab
- Where
- 30 sites in United States, Argentina and 9 more
- Volunteers
- 26 people
- Sponsor
- Immunovant Sciences GmbH
Guillain Barré Syndrome
Upper Limb Robot-Assisted Therapy in Patients With Guillain-Barré Syndrome
Guillain-Barré Syndrome is an immune-mediated polyradiculoneuropathy, with around 100,000 new cases reported worldwide annually.
- Trial name
- RAUL-Project (NCT06620198)
- Testing
- Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming, Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia